8284
E. Jablonkai et al. / Tetrahedron 70 (2014) 8280e8285
7H, skeletal CH2, CH), 4.55e4.74 (m, 1H, OCH); IR (neat) 1059, 1229,
1458, 2960 cmꢂ1; ½M þ Hꢃfþound ¼ 177:1039; C8H18O2P requires
177.1039.
1.29e1.75 (m, 6H, skeletal CH2, CH), 1.93e2.08 (m, 2H, CH2CH3),
3.84e3.96 (m, 2H, OCH2); IR (neat) 1064, 1243, 1456, 2965 cmꢂ1
,
½M þ Hꢃþfound ¼ 191:1197; C9H20O2P requires 191.1195.
4.2.7. 1-Isobutoxy-3-methylphospholane 1-oxide (10f). 31P NMR
4.2.12. 1-Isopropoxy-3,4-dimethylphospholane 1-oxide (12d). 31P
(CDCl3)
d
: 79.2; 13C NMR (CDCl3)
d
: isomer A: 18.7 (CHCH3), 21.2 (d, J
NMR (CDCl3)
(CDCl3) : 18.9 (d, J 14.9, C3eCH3 or C4eCH3),19.1 (d, J 14.1, C4eCH3 or
d
: 70.9 (A, 95%), 77.4 (B, 3%) and 76.9 (C, 2%); 13C NMR
7.0, C3eCH3), 25.2 (d, J 88.2, C5), 29.2 (d, J 6.3, OCH2CH), 31.2 (d, J 9.7,
C4 or C3), 31.8 (d, J 13.0, C3 or C4), 32.7 (d, J 89.8, C2), 70.46 (d, J 6.9,
OCH2); isomer B: 18.7 (CHCH3), 21.4 (d, J 6.2, C3eCH3), 25.9 (d, J 87.7,
C5), 29.2 (d, J 6.3, OCH2CH), 31.4 (d, J 9.8, C4 or C3), 32.0 (d, J 13.1, C3
d
C3eCH3), 24.2 and 24.3 (d, J 4.0 and J 3.7, OCHCH3), 35.3 (d, J 88.6, C5
or C2), 35.6 (d, J 88.4, C2 or C5), 38.7 (d, J 10.8, C3 and C4), 69.3 (d, J 6.6,
OCH); 1H NMR (CDCl3)
d: 1.06 (br d, Jw4.8) and 1.07 (br d, Jw4.8, total
or C4), 33.0 (d, J 89.3, C2), 70.51 (d, J 6.9, OCH2); 1H NMR (CDCl3)
d:
intensity 6H, C3eCH3/C4eCH3), 1.31 (br d, J 6.2, 6H, CHCH3),
1.31e2.09 (m, 6H, skeletal CH2, CH), 4.60e4.71 (m, 1H, OCH); IR
(neat) 1065, 1244, 1457, 2961 cmꢂ1; ½M þ Hꢃfþound ¼ 191:1197;
C9H20O2P requires 191.1195.
0.79 (d, J 6.6) and 0.80 (d, J 6.6) total intensity 6H, CHCH3, 0.96 (d, J
5.0, 3H, C3eCH3), 1.08e2.04 (m, 8H, skeletal CH2, CH, CH2CH),
3.52e3.72 (m, 2H, OCH2); IR (neat) 1023, 1228, 1458, 2959 cmꢂ1
½M þ Hꢃþfound ¼ 191:1195; C9H20O2P requires 191.1195.
;
4.2.13. 1-Isobutoxy-3,4-dimethylphospholane 1-oxide (12f). 31P NMR
4.2.8. 1-(1-Methylpropoxy)-3-methylphospholane 1-oxide (10g). 31P
NMR (CDCl3)
: 77.8 (A and B, 46% [on the basis of the relative 13C
NMR intensities of the signals of the C5 atom, the ratio of A and B is
1:1]), 78.0 (C, 32%) and 77.9 (D, 22%); 13C NMR (CDCl3)
: isomer A:
(CDCl3)
(CDCl3) d: 18.9 (CHCH3), 19.0 (d, J 17.1, C3eCH3 or C4eCH3), 19.2 (d, J
d
: 72.7 (A, 94%), 79.3 (B, 3%) and 78.5 (C, 3%); 13C NMR
d
14.8, C4eCH3 or C3eCH3), 29.3 (d, J 6.3, OCH2CH), 34.3 (d, J 88.6, C5 or
C2), 34.7 (d, J 88.3, C2 or C5), 38.8 (d, J 10.8, C3 and C4), 70.6 (d, J 6.9,
d
9.7 (CH2CH3), 21.3 (d, J 15.1, C3eCH3), 21.74 (d, J 7.9, CHCH3), 26.1 (d,
J 88.3, C5), 30.69 (d, J 5.2, CHCH2), 31.3 (d, J 9.7, C4 or C3), 31.9 (d, J
13.4, C3 or C4), 33.6 (d, J 89.9, C2), 74.06 (d, J 7.1, OCH); isomer B: 9.7
(CH2CH3), 21.3 (d, J 15.1, C3eCH3), 21.74 (d, J 7.9, CHCH3), 26.6 (d, J
88.3, C5), 30.69 (d, J 5.2, CHCH2), 31.4 (d, J 9.1, C4 or C3), 31.94 (d, J
13.4, C3 or C4), 33.9 (d, J 89.5, C2), 74.08 (d, J 6.8, OCH); isomer C: 9.7
(CH2CH3), 21.4 (d, J 14.4, C3eCH3), 21.77 (d, J 8.0, CHCH3), 26.8 (d, J
88.1, C5), 30.71 (d, Jw5, CHCH2), 31.5 (d, J 9.3, C4 or C3), 32.04 (d, J
13.0, C3 or C4), 34.0 (d, J 89.9, C2), 74.2 (d, J¼7.1, OCH); isomer D: 9.7
(CH2CH3), 21.4 (d, J 14.4, C3eCH3), 21.71 (d, J 8.0, CHCH3), 27.3 (d, J
88.0, C5), 30.8 (d, Jw5, CHCH2), 31.6 (d, J 9.7, C4 or C3), 32.12 (d, J
13.6, C3 or C4), 34.4 (d, J 89.5, C2), 74.3 (d, J 6.9, OCH); 1H NMR
OCH2); 1H NMR (CDCl3)
d: 0.88 (d, J 6.7, 6H, CHCH3),1.03 (br d, Jw5.0,
6H, C3eCH3/C4eCH3), 1.26e2.08 (m, 7H, skeletal CH2, CH, OCH2CH),
3.60e3.77 (m, 2H, OCH2); IR (neat) 1024, 1244, 1456, 2961 cmꢂ1
½M þ Hꢃþfound ¼ 205:1355; C10H22O2P requires 205.1352.
;
4.2.14. 1-(1-Methylpropoxy)-3,4-dimethylphospholane 1-oxide
(12g). 31P NMR (CDCl3)
: 71.2 (A, 49%), 71.3 (B, 47%), 77.3 (C, 2%)
and 77.8 (D, 2%); 13C NMR (CDCl3)
: isomer A: 9.6 (CH2CH3), 18.8 (d, J
d
d
15.3, C3eCH3 or C4eCH3), 19.1 (d, J 14.5, C4eCH3 or C3eCH3), 21.6 (d, J
2.8, OCHCH3), 30.6 (d, J 5.3, CHCH2), 35.0 (d, J 88.8, C5 or C2), 35.4 (d, J
88.7, C2 or C5), 38.6 (d, J 10.9, C4 or C3), 38.66 (d, J 10.8, C3 or C4), 74.0
(d, J 7.0, OCH); isomer B: 9.6 (CH2CH3), 18.8 (d, J 15.3, C3eCH3 or
C4eCH3), 19.1 (d, J 14.5, C4eCH3 or C3eCH3), 21.8 (d, J 2.4, OCHCH3),
30.7 (d, J 5.1, CHCH2), 35.3 (d, J 88.5, C5 or C2), 35.8 (d, J 88.6, C2 or C5),
38.66 (d, J 10.8, C4 or C3), 38.71 (d, J 10.6, C3 or C4), 74.2 (d, J 7.0, OCH);
(CDCl3) d: 0.88 (t, J 7.3, 3H, CH2CH3), 1.05 (d, J 4.7, 3H, C3eCH3), 1.26
(d, J 6.1, 3H, CHCH3), 1.10e141 (m, 2H, CHCH2), 1.45e2.15 (m, 7H,
skeletal CH2, CH), 4.27e4.48 (m, 1H, OCH); IR (neat) 1030, 1228,
1458, 2967 cmꢂ1; ½M þ Hꢃfþound ¼ 191:1196; C9H20O2P requires
191.1195.
1H NMR (CDCl3)
d: 0.90 (t, J 7.4, 3H, CH2CH3), 1.05 (br d, Jw4.8) and
1.06 (br d, Jw4.8, total intensity 6H, C3eCH3/C4eCH3), 1.28 (d, J 6.2,
3H, CHCH3), 1.37e2.04 (m, 8H, skeletal CH2, CH, CHCH2), 4.30e4.45
4.2.9. 1-Methoxy-3,4-dimethylphospholane 1-oxide (12a). 31P NMR
(m, 1H, OCH); IR (neat) 1031, 1239, 1457, 2966 cmꢂ1; ½M þ Hꢃfþound
¼
(CDCl3)
(CDCl3)
d
: 74.7 (A, 91%), 81.3 (B, 6%) and 80.6 (C, 3%); 13C NMR
205:1352; C10H22O2P requires 205.1352.
d: 18.9 (d, J 15.7, C3eCH3 or C4eCH3), 19.1 (d, J 14.7, C4eCH3
The identification of the known compounds (3aef, 3h, 6aec, 6e,
8aef, 10e and 12e) is given in Table 7.
or C3eCH3), 33.8 (d, J 88.4, C5 or C2), 34.1 (d, J 87.9, C2 or C5), 38.6 (d,
J 10.8, C4 or C3), 38.7 (d, J 10.8, C3 or C4), 51.1 (d, J 6.7, OCH3); 1H NMR
Table 7
(CDCl3) d: 1.05 (br d, J 4.7, total intensity 6H, C3eCH3/C4eCH3),
Selected spectral data for the known esters (3aef, 3h, 6aec, 6e, 8aef, 10e and 12e)
1.24e2.10 (m, 6H, skeletal CH2, CH), 3.65 (d, J 10.8, 3H, OCH3); IR
(neat) 1033, 1242, 1456, 2961 cmꢂ1; ½M þ Hꢃfþound ¼ 163:0886;
C7H16O2P requires 163.0888.
Product
31P NMR (CDCl3)
dP (lit.)
½M þ Hꢃþfound
½M þ Hꢃþrequires
3a
3b
3c
3d
3e
3f
3h
6a
6b
6c
6e
8a
8b
8c
8d
8e
8f
27.2
25.7
25.0
22.3
25.7
25.2
15.2
33.4
31.4
31.2
31.2
70.5
68.5
68.6
66.8
68.5
67.6
79.4
27.6 [14]
24.7 [15]
24.9 [15]
22.3 [15]
24.9 [15]
25.0 [15]
15.3 [16]
34.5 [17]
30.8 [18]
33.5 [19]
31.2 [15]
70.1 [20]
68.3 [11]
68.5 [15]
66.8 [11]
68.4 [15]
68.5 [15]
79.40 (50%)
79.38 (50%) [8]
72.5 (60%)
78.4 (20%)
79.0 (20%) [8]
157.0423
171.0575
185.0733
185.0733
199.0888
199.0887
199.0888
233.0737
247.0888
261.1040
275.1196
161.0730
175.0887
188.0955a
188.0959a
203.1203
203.1204
191.1204
157.0413
171.0575
185.0731
185.0731
199.0888
199.0888
199.0888
233.0737
247.0888
261.1039
275.1195
161.0731
175.0888
188.0966a
188.0966a
203.1201
203.1201
191.1201
4.2.10. 1-Ethoxy-3,4-dimethylphospholane 1-oxide (12b). 31P NMR
(CDCl3)
(CDCl3)
d
: 72.6 (A, 92%), 79.1 (B, 5%) and 78.5 (C, 3%); 13C NMR
d
: 16.4 (d, J 6.0, CH2CH3), 18.7 (d, J 15.1, C3eCH3 or C4eCH3),
18.9 (d, J 14.2, C4eCH3 or C3eCH3), 34.3 (d, J 88.5, C5 or C2), 34.6 (d, J
88.1, C2 or C5), 38.50 (d, J 10.8, C4 or C3), 38.54 (d, J 10.9, C3 or C4),
60.4 (d, J 6.5, OCH2); 1H NMR (CDCl3)
d: 1.01 (br d, Jw4.4, total in-
tensity 6H, C3eCH3/C4eCH3), 1.24 (t, J 7.0) and 1.25 (t, J 7.0), total
intensity 3H, CH2CH3, 1.15e2.02 (m, 6H, skeletal CH2, CH),
3.89e4.10 (m, 2H, OCH2); IR (neat) 1035, 1242, 1455, 2963 cmꢂ1
½M þ Hꢃþfound ¼ 177:1042; C8H18O2P requires 177.1039.
;
4.2.11. 1-Propoxy-3,4-dimethylphospholane 1-oxide (12c). 31P NMR
(CDCl3)
(CDCl3)
d
: 72.6 (A, 94%), 78.5 (B, 3%) and 79.2 (C, 3%); 13C NMR
: 10.0 (CH2CH3), 18.7 (d, J 15.3, C3eCH3 or C4eCH3), 19.0 (d,
10e
d
12e
72.4 (92%)
78.3 (3%)
79.0 (5%)
205.1350
205.1357
J 14.4, C4eCH3 or C3eCH3), 23.8 (d, J 6.2, OCH2CH2), 33.8 (d, J 88.5, C5
or C2), 35.0 (d, J 88.2, C2 or C5), 38.5 (d, J 10.8, C4 or C3), 38.6 (d, J 10.9,
C
3 or C4), 65.9 (d, J 6.7, OCH2); 1H NMR (CDCl3)
d: 0.91 (t, J 7.4, 3H,
a
For the unprotonated M.
CH2CH3), 1.05 (br d, Jw4.7, total intensity 6H, C3eCH3/C4eCH3),